R&D channel feed

Ul­tragenyx touts Phase 3 win for gene ther­a­py in rare glyco­gen stor­age dis­or­der

11 months ago
Cell/Gene Tx

Gilead’s block­buster ADC Trodelvy fails blad­der can­cer con­fir­ma­to­ry study

11 months ago
Pharma
FDA+

Sum­mit Ther­a­peu­tics touts a rare tri­umph over Keytru­da in lung can­cer from a Chi­na-on­ly Phase 3 study

11 months ago

The bio­phar­ma news we’re pay­ing at­ten­tion to at AS­CO

11 months ago

No­var­tis ends de­vel­op­ment of KRAS drug, cit­ing 'in­creas­ing op­tions avail­able'

11 months ago
Pharma

Flush with cash, No­vo Nordisk Foun­da­tion now plans to rein­vest some GLP-1 prof­its in­to re­gen­er­a­tive med­i­cines

11 months ago
Cell/Gene Tx

Bridge­Bio touts ad­di­tion­al AT­TR-CM drug da­ta in new analy­ses of Phase 3 tri­al

11 months ago

Im­muno­vant post­pones tri­al read­outs for its late-stage FcRn drug as it pri­or­i­tizes an­oth­er

11 months ago

Ar­row­head plots next steps for RNAi ther­a­pies af­ter mid-stage win in mixed hy­per­lipi­demia

11 months ago

Bio­haven’s au­toim­mune drug dis­ap­points in­vestors in study of healthy vol­un­teers 

11 months ago

J&J's ma­jor de­pres­sive dis­or­der drug hits end­points in Phase 3 tri­al

11 months ago

Ike­na On­col­o­gy weighs ‘strate­gic op­tions’ as it drops can­cer as­set, trims head­count to save cash

11 months ago
People

Arc­turus teas­es da­ta from small tri­al of in­hal­able cys­tic fi­bro­sis mR­NA ther­a­py, stock rock­ets 

11 months ago

As­traZeneca re­veals ear­ly da­ta for oral PC­SK9, touts PK edge over Mer­ck’s drug

11 months ago

Sec­ond en­gi­neered B cell ther­a­py en­ters the clin­ic, promis­ing to do in he­mo­phil­ia B what gene ther­a­pies can't

11 months ago
Cell/Gene Tx
FDA+

In­smed stock sky­rock­ets on Phase 3 lung dis­ease da­ta

11 months ago

NewAms­ter­dam says for­mer Am­gen car­dio drug re­duces heart dis­ease risk fac­tor

11 months ago

Duchenne mus­cu­lar dy­s­tro­phy drug flunks Phase 3 con­fir­ma­to­ry tri­al

11 months ago

Cor­rect­ed: As­traZeneca, Dai­ichi Sankyo’s TROP2 ADC boosts sur­vival in Phase 3 lung can­cer sub­group

11 months ago

#AS­CO24: Merus, tout­ing more Phase 2 da­ta, plots piv­otal head and neck can­cer tri­al in first-line set­ting

11 months ago

No­var­tis to seek ap­provals in two rare kid­ney dis­eases af­ter pos­i­tive Phase 3 tri­als

11 months ago

Ve­rastem's stock takes a hit af­ter shar­ing up­dat­ed fil­ing plans in ovar­i­an can­cer

11 months ago

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers

11 months ago

HI-Bio out­lines da­ta that sparked $1.15B Bio­gen buy­out

11 months ago
First page Previous page 40414243444546 Next page Last page
A service from the Financial Times